LUMAKRAS is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
*Includes 93% commercial, 99% Medicare, 97% Managed Medicaid, and 94% State Medicaid coverage.
Connect with us live:
Call 1-888-4ASSIST
(1-888-427-7478)
Call 1-888-4ASSIST
(1-888-427-7478)
Monday through Friday —
9:00 am to 8:00 pm ET
BENEFITS VERIFICATION Submit, store, and retrieve benefit verifications for all patients currently on Amgen medications electronically with ease from our secure Amgen Assist 360™ Provider Portal.
REIMBURSEMENT COUNSELORS Call an Amgen Reimbursement Counselor directly for your benefit verification needs.
FIELD REIMBURSEMENT SPECIALISTS Schedule a remote or live appointment with a Field Reimbursement Specialist who can assist with:
Patients are connected with a single point of contact who can help them find resources that are most important to them.† Amgen Nurse Navigators are there to support, not replace, your treatment plan and are trained to assist a patient with financial coverage and referrals to resources that may help their emotional wellness throughout their treatment journey.‡
Financial and co-pay assistance
For eligible§ commercially insured patients, the Amgen SupportPlus Co-Pay Program can help.
Medication answers
If your patients have questions about their Amgen medication, we can help them get the answers they need.
Referrals to day-to-day living resources
Patients can learn about independent nonprofit organizations that may provide community resources, one-on-one counseling services, and local support groups.
†Resources include referrals to independent nonprofit patient assistance programs. Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit’s criteria. Amgen has no control over these programs and provides referrals as a courtesy only.
‡Amgen Nurse Navigators are only available to patients that are prescribed certain products. Nurse Navigators are there to support, not replace, your treatment plan and do not provide medical advice or case management services. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.
§Terms, conditions, and program maximums apply. This program is not open to patients receiving prescription reimbursement under any federal-, state-, or government-funded healthcare program. Not valid where prohibited by law.
Helping eligible patients save on out-of-pocket costs
The Amgen SupportPlus Co-Pay Program is here to help eligible commercially insured patients pay for their out-of-pocket prescription costs.
**$25 out-of-pocket cost for each dose of Prolia (denosumab) and EVENITY (romosozumab-aqqg) through Amgen SupportPlus.
††Terms, conditions, and program maximums apply. Other restrictions may apply. See the Amgen SupportPlus Co-Pay Program Terms and Conditions for details. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.
There are three easy ways to help patients submit their
enrollment form for Amgen Assist 360™
Call
1-888-4ASSIST
(1-888-427-7478)
Monday through Friday
9 am to 8 pm ET
Call
1-888-4ASSIST
(1-888-427-7478)
Monday through Friday
9 am to 8 pm ET
Fax
1-888-407-9787
Mail
PO Box 220354
Charlotte, NC
28222-9924
Connect with us
Call
1-888-4ASSIST
(1-888-427-7478) amgenassist360.com
Monday through Friday — 9:00 am to 8:00 pm ET
There are multiple ways for patients to receive LUMAKRAS, depending on their insurance. These options include national specialty pharmacies, dispensing oncology clinics, and others.
Hepatotoxicity
Interstitial Lung Disease (ILD)/Pneumonitis
Most common adverse reactions
Drug interactions
INDICATION
LUMAKRAS is indicated for the treatment of adult patients with KRAS G12C‑mutated locally advanced or metastatic non‑small cell lung cancer (NSCLC), as determined by an FDA‑approved test, who have received at least one prior systemic therapy.
This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Please see full Prescribing Information.
Important Safety Information
Hepatotoxicity